Efficacy News and Research

RSS
Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

Symposium discusses about novel approaches to bacterial caries management

Symposium discusses about novel approaches to bacterial caries management

FDA Neurological Devices Advisory Panel voted to recommend approval for Pipeline Embolization Device

FDA Neurological Devices Advisory Panel voted to recommend approval for Pipeline Embolization Device

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

Quark Pharmaceuticals receives results from Phase 2 trial of PF-04523655 in patients with DME

Quark Pharmaceuticals receives results from Phase 2 trial of PF-04523655 in patients with DME

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Richmont obtains PURE's IV-7 Germ Defense disinfectant registration in South Africa

Richmont obtains PURE's IV-7 Germ Defense disinfectant registration in South Africa

Science journal publishes CYTK preclinical cardiac myosin activation research results

Science journal publishes CYTK preclinical cardiac myosin activation research results

KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction

KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

Researchers develop diagnostic test for motor neurone disease

Researchers develop diagnostic test for motor neurone disease

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

Nationwide observance raises awareness about HIV/AIDS spread in women

Nationwide observance raises awareness about HIV/AIDS spread in women

pIMAGO nanopolymer can test cancer drug efficacy against biochemical processes

pIMAGO nanopolymer can test cancer drug efficacy against biochemical processes

Beike, ThermoGenesis enter agreement to employ new technology for stem cell therapies

Beike, ThermoGenesis enter agreement to employ new technology for stem cell therapies

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.